Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Nurses Open To Idea Of Robots
Front-line staff in the nursing and care sector would welcome sensor and robot technology in nursing homes and the homes of elderly people.
generic viagra online
New Pre-Clinical Data On OmniGuide's BeamPath NEURO(TM) Demonstrates Precise Cutting In Brain Tissue
OmniGuide, Inc., the developer of the first and only flexible CO2 laser fiber based on breakthrough photonic bandgap technology, announced the results of a pre-clinical study comparing the Company"s fiber scalpels to conventional incision methods in neurosurgery. In the study, surgeons from the Barrow Neurological Institute reported that careful studies of incisions produced in live brain tissue with fiber delivered CO2 laser radiation produced precise cuts while minimally effecting adjacent brain tissue when compared with a widely used reference technique. The study, led by Drs. Mark Preul, Robert W. Ryan, and Robert Spetzler of the Neurosurgery Research Laboratory, Barrow Neurological Institute, in Phoenix, Arizona, was presented at the annual conference of the American Academy of Neurological Surgeons in San Diego, California.
News of the day
Medarex Announces Primary Endpoint Achieved In MDX-1100 Anti-IP-10 Antibody Phase 2 Trial For Rheumatoid Arthritis
Medarex, Inc. (Nasdaq: MEDX) announced that the MDX-1100 Phase 2 proof-of-concept trial in patients with active rheumatoid arthritis (RA) receiving methotrexate successfully met its primary endpoint. The top-line results from the recently completed 70-patient multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated that when compared to placebo, three times the number of patients treated with 10 mg/kg of MDX-1100 every two weeks achieved at least a 20% improvement in RA signs and symptoms at 12 weeks, the primary endpoint of the study, as measured by the American College of Rheumatology (ACR) 20 measurement of response. These results were statistically significant when compared with placebo (p=0.0024). The antibody combination with methotrexate was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.
Public Health

New Study Uncovers Mode Of Action Of Enzyme Linked With Several Types Of Cancer

Scientists at the Institute for Research in Immunology and Cancer (IRIC) of the Universitçİ de Montrçİal have discovered a key mechanism used by cells to efficiently distribute chromosomes to new cells during cell multiplication. Published in the journal Molecular Cell, the study is the first to demonstrate that this mechanism relies on the polo kinase, an enzyme implicated in several cancers. Inhibiting this mechanism could be key to developing effective therapies to treat cancer. Each human cell contains, in its nucleus, all the coding instructions necessary to direct the cell"s activities. A complete set of those instructions is referred to as a genome. Cancer cells are capable of altering their genome in order to promote uncontrolled growth. "Cancer cells achieve this by gaining or losing specific chromosomes, or by inducing structural defects in their genome," explains Damien D"Amours, Principal Investigator at IRIC and director of the study, "We discovered that the polo kinase, overexpressed in a broad range of human tumours, tells the chromosomes exactly when to condense during cell division." Misregulation of the polo kinase is associated with cancers, thereby suggesting a link between defects in chromosome condensation and the formation of tumours. "Pharmaceutical companies and independent researchers are already working on the development of new cancer drugs to inhibit the activity of the polo kinase," points out Damien D"Amours, "Understanding this enzyme"s mode of action should enable us to control it. Such knowledge may reveal itself to be key in developing effective therapies to treat cancer." In a preview article commissioned by Molecular Cell, world leader in chromosome dynamics Tatsuya Hirano, of the Riken Advanced Science Institute in Japan, qualifies the research as a tour de force study that will help address outstanding questions in the field. Carolyne Lord University of Montreal


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

İ Copyright 2009